Category - Developments

Developments

Health Canada clears Scientus Pharma to make cannabis soft gel capsules and oils

Closely-held Scientus Pharma received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art commercial production facility in Whitby, Ontario. “At Scientus Pharma, our main...

October 22, 2018

Developments

Scientific American article explores why some doctors reject tools that make their jobs easier

In the latest edition of Scientific American online, Dr. Gina Siddiqui, an emergency room doctor at Yale New Haven Hospital, discusses why physicians have incorrectly feared that new technology would make their jobs...

October 17, 2018

Developments

Ortho RTi presents rotator cuff repair study at SICOT orthopedic congress

Ortho Regenerative Technologies (CSE:ORTH) presented a poster entitled, “Freeze-dried [Ortho-R] in Platelet-rich Plasma in Sheep Model of Rotator Cuff Repair,” at the SICOT Orthopaedic World Congress in Montreal. The...

October 11, 2018

Developments

CHF Solutions in collaboration with NI Medical on fluid overload

CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...

October 11, 2018

Developments

IntelGenx partner, Insud Pharma, submits ANDA for generic buccal product

IntelGenx’s (TSXV:IGX; OTCQX:IGXT) partner, Insud Pharma (formerly Chemo Group), submitted an abbreviated new drug application (ANDA) with the FDA for a generic buccal film product. “The filing of an ANDA for this...

October 4, 2018

Developments

BioLight completes second stage in sale of IOPtima unit

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the second stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the...

September 27, 2018

Developments

IntelGenx beginning patient screening in Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that patient recruitment would begin for a Phase 2a study with Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s Disease (AD). Two research sites in Toronto...

September 25, 2018

Developments

Aurinia Pharma completes enrollment in Phase 3 AURORA trial for LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has completed enrollment for the Phase 3 AURORA trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus...

September 25, 2018

Developments

IntelGenx posts successful bioequivalence study results for RIZAPORT

IntelGenx (TSXV:IGX; OTCQX:IGXT) reported successful results from a bioequivalence study for RIZAPORT, its proprietary anti-migraine VersaFilm product, demonstrating that RIZAORT is bioequivalent to the U.S. reference...

September 24, 2018

Developments

IntelGenx to Partner with Tilray to produce cannabis-infused oral film products

IntelGenx (TSX-V:IGX; OTCQX:IGXT) executed a non-binding letter of intent with Tilray (NASDAQ:TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis in anticipation of...

September 20, 2018

Category - Developments

Subscribe